指南与共识瓣膜外科

生物瓣二尖瓣耐久性改善是否应降低二尖瓣置换的年龄指南推荐

Should mitral valve replacement age guidelines be lowered due to better bioprosthetic mitral valve durability?
指南 / 共识 · J Thorac Cardiovasc Surg · 2023-10-13

该回顾性研究纳入2004至2020年两家大学心脏外科中心1544例生物瓣二尖瓣置换患者,按年龄十分位比较结构性瓣膜衰败,发现40至70岁患者结构性瓣膜衰败无统计学差异(P=0.1),10年及12年再干预累积发生率分别为6.2%和9.0%,作者认为牛心包二尖瓣置换对年轻患者是耐久选择,这些见解或可为修订当前指南提供数据。

要点

  • 40至70岁患者结构性瓣膜衰败无统计学差异(P=0.1)。
  • 全组二尖瓣再干预累积发生率10年为6.2%,12年为9.0%。
  • 作者认为牛心包二尖瓣置换对年轻患者是耐久选择。

核心结论

  • 作者认为牛心包二尖瓣置换对年轻患者是耐久选择。
  • 避免抗凝及机械二尖瓣置换相关风险可能对患者有益。
  • 这些见解或可为修订当前指南提供所需数据。

研究设计与样本

  • 回顾性研究,纳入2004至2020年两家大学心脏外科中心接受生物瓣二尖瓣置换的患者,随访至2022年6月。
  • 共1544例可用患者,平均年龄66±13岁,652例(42%)年龄小于65岁。

主要发现

  • 二尖瓣置换指征:二尖瓣反流大于2+为53%(n=813),二尖瓣狭窄为44%(n=650),心内膜炎为18%(n=277),再次手术为39%(n=602)。
  • 合并手术:主动脉瓣置换28%(n=426),三尖瓣手术36%(n=550),冠状动脉旁路移植19%(n=290)。
  • 30天死亡率为5.4%。
  • 随访(临床:中位数[四分位距]75[25-129]个月)中,因心内膜炎再手术和新发卒中发生率低(分别为每100患者年0.30和1.06)。
  • 全组因结构性瓣膜衰败行二尖瓣再干预的累积发生率10年为6.2%,12年为9.0%,40至70岁患者结构性瓣膜衰败无统计学差异(P=0.1)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Guideline recommendations for mechanical or bioprosthetic valve for mitral valve replacement by age remains controversial. We sought to determine bovine pericardial valve durability by age and risk of reintervention. METHODS: This retrospective study between 2 large university-based cardiac surgery programs examined patients who underwent bioprosthetic mitral valve replacement from 2004 to 2020. Follow-up was obtained through June 2022. Durability outcomes involving structural valve deterioration were compared by age decile. RESULTS: Of 1544 available patients, mean age was 66 ± 13 years and 652 (42%) were aged less than 65 years. Indications for mitral valve replacement were as follows: mitral regurgitation greater than 2+ in 53% (n = 813), mitral stenosis in 44% (n = 650), endocarditis in 18% (n = 277), and reoperation in 39% (n = 602). Concomitant procedures were aortic valve replacement in 28% (n = 426), tricuspid valve in 36% (n = 550), and coronary artery bypass in 19% (n = 290). Thirty-day mortality was 5.4%. In follow-up (clinical: median [interquartile range] 75 [25-129] months), reoperation for endocarditis and new stroke were low (0.30 and 1.06 per 100 patient/years, respectively). The cumulative incidence of mitral valve reintervention for structural valve deterioration among all patients was 6.2% at 10 years and 9.0% at 12 years with no statistical difference in structural valve deterioration in patients aged 40 to 70 years (P = .1). In 90 patients with mitral valve reintervention, 30-day mortality after reintervention was 4.7% (n = 2) for 43 with mitral valve-in-valve and 6.4% (n = 3) for 47 with reoperation. CONCLUSIONS: Bovine pericardial mitral valve replacement is a durable option for younger patients. The opportunity to avoid anticoagulation and the associated risks with mechanical mitral valve replacement may be of benefit to patients. These insights may provide data needed to revise the current guidelines.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Romano M, McCarthy PM, Baldridge AS, et al. Should mitral valve replacement age guidelines be lowered due to better bioprosthetic mitral valve durability? J Thorac Cardiovasc Surg. 2023. PMID: 37839657. doi:10.1016/j.jtcvs.2023.10.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。